4-(pyrrolidin-1-ylmethyl)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(pyrrolidin-1-ylmethyl)benzoic acid
• 英文别名: 4-(pyrrolidin-1-ium-1-ylmethyl)benzoate
• 化学式: C₁₂H₁₅NO₂
• mdl: MFCD05240081
• 分子量: 205.257
• InChiKey: DOEIPZUTRVMWAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(pyrrolidin-1-ylmethyl)benzoic acid 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-Pyrrolidin-1-ylmethyl-benzoyl chloride
  参考文献：
  名称：

  Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

  摘要：

  In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.001
• 作为产物：
  描述：

  3-甲醛苯甲酸甲酯 在 水 、 lithium hydroxide 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 18.0h， 生成 4-(pyrrolidin-1-ylmethyl)benzoic acid
  参考文献：
  名称：

  PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

  摘要：

  这项发明涉及USP7抑制剂，用于治疗癌症、神经退行性疾病、免疫紊乱、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病、细菌感染和疾病，具有以下结构式： 其中m、n、X1、X2、R1-R5、R5'和R6如本文所述。

  公开号：

  US20160185785A1

文献信息

• PHENYLALANINE DIPEPTIDE DERIVATIVES, COMPOSITIONS AND USE THEREOF
  申请人：Liang Guangyi

  公开号：US20090247470A1

  公开（公告）日：2009-10-01

  Disclosed are a compound of formula I, stereoisomers, pharmaceutically acceptable salts or hydrates thereof, a pharmaceutical composition comprising the smae, a process for preparing the same and use thereof. The compound may also be used to prepare a medicament to treat viral infections, especially to prepare a medicament to treat hepatitis B virus and human immunodeficiency virus with little toxic side effects.

  公开了一种具有I式化合物、立体异构体、药学上可接受的盐或水合物的化合物，包括该化合物的药物组合物，制备该化合物的方法以及其用途。该化合物还可用于制备治疗病毒感染的药物，特别是用于制备治疗乙型肝炎病毒和人类免疫缺陷病毒的药物，具有较小的毒副作用。
• [EN] MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS POUR LE RÉCEPTEUR MAS COUPLÉ À LA PROTÉINE G ET TRAITEMENT DES TROUBLES QUI Y SONT APPARENTÉS
  申请人：ARENA PHARM INC

  公开号：WO2013070657A1

  公开（公告）日：2013-05-16

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.

  本发明涉及式（I）化合物及其药用可接受的盐、溶剂和水合物，这些化合物在治疗和缓解由缺血引起的心脏、脑、肾脏、免疫系统和生殖系统的疾病和紊乱方面具有用处，或者在缺血后再灌注引起的疾病和障碍，以及与之相关的任何下游并发症。本发明还涉及治疗和缓解由血管收缩或高血压引起的血管疾病和障碍的方法，以及由高血压和/或组织灌注减少引起的任何下游并发症。
• [EN] CYCLIC PHOSPHATES AND CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF NEUROLOGIC DISORDERS<br/>[FR] PHOSPHATES CYCLIQUES ET PHOSPHORAMIDATES CYCLIQUES POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：RETROPHIN INC

  公开号：WO2017099822A1

  公开（公告）日：2017-06-15

  Compounds having the following formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, D, E and R1 are as defined herein, are provided. Methods comprising the use of such compounds for the treatment of neurological disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in the treatment of neurological disorders, also are provided.

  提供具有以下化学式（I）的化合物及其药用可接受的盐，其中A、B、D、E和R1的定义如本文所述。提供了使用这些化合物治疗神经系统疾病（如泛酸激酶相关性神经退行性疾病）的方法，以及含有这些化合物的药物组合物，以及它们在治疗神经系统疾病中的用途。
• Discovery of an MLLT1/3 YEATS Domain Chemical Probe
  作者：Moses Moustakim、Thomas Christott、Octovia P. Monteiro、James Bennett、Charline Giroud、Jennifer Ward、Catherine M. Rogers、Paul Smith、Ioanna Panagakou、Laura Díaz-Sáez、Suet Ling Felce、Vicki Gamble、Carina Gileadi、Nadia Halidi、David Heidenreich、Apirat Chaikuad、Stefan Knapp、Kilian V. M. Huber、Gillian Farnie、Jag Heer、Nenad Manevski、Gennady Poda、Rima Al-awar、Darren J. Dixon、Paul E. Brennan、Oleg Fedorov

  DOI：10.1002/anie.201810617

  日期：2018.12.10

  YEATS domain (YD) containing proteins are an emerging class of epigenetic targets in drug discovery. Dysregulation of these modified lysine-binding proteins has been linked to the onset and progression of cancers. We herein report the discovery and characterisation of the first small-molecule chemical probe, SGC-iMLLT, for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3). SGC-iMLLT is a potent and

  包含YEATS域（YD）的蛋白质是药物发现中新兴的表观遗传学目标。这些修饰的赖氨酸结合蛋白的失调与癌症的发生和发展有关。我们在此报告了针对MLLT1（ENL / YEATS1）和MLLT3（AF9 / YEATS3）的YD的第一个小分子化学探针SGC-iMLLT的发现和表征。SGC-iMLLT是一种有效且选择性的MLLT1 / 3-组蛋白相互作用抑制剂。观察到对其他人类YD蛋白（YEATS2 / 4）和溴结构域具有出色的选择性。此外，我们的探针显示了MLLT1和MLLT3的细胞靶标接合。还报道了具有MLLT1 YD的第一个小分子X射线共晶体结构。
• [EN] TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE ASK
  申请人：SERONO LAB

  公开号：WO2009027283A1

  公开（公告）日：2009-03-05

  The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatorydiseases, cardiovascular disceases and/or neurodegenerative diseases and a process for their preparation.

  本发明涉及三唑吡啶化合物，其化学式为（I），其用作药物，用于治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病，以及其制备方法。